Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Malignant Lymphoma

  Free Subscription


05.10.2026

1 Am J Hematol
4 Blood
1 BMC Cancer
2 Br J Haematol
1 Cancer Lett
1 Eur J Haematol
4 Haematologica
1 Hum Pathol
1 J Natl Cancer Inst
1 Leukemia
1 Neurology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. BEAUVAIS D, Zirem Y, Cardon T, Aboulouard S, et al
    Proteomic Profiling of Nodal T-Follicular Helper Cell Lymphoma Reveals Distinct Biological Signatures and Improves Prognostic Stratification Beyond the IPI.
    Am J Hematol. 2026 Oct 1. doi: 10.1002/ajh.70502.
    PubMed         Abstract available


    Blood

  2. PATEL K, Shah GL, Schoder H, Ganesan N, et al
    Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.
    Blood. 2026 Sep 8:blood.2026035115. doi: 10.1182/blood.2026035115.
    PubMed         Abstract available

  3. GROMMES C, Nayak L, Kallam A, Peereboom D, et al
    Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.
    Blood. 2026 Oct 1:blood.2026034926. doi: 10.1182/blood.2026034926.
    PubMed         Abstract available

  4. AHMED S, Martin Garcia-Sancho A, Reguera Ortega JL, Cartron G, et al
    Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.
    Blood. 2026;148:1789-1799.
    PubMed         Abstract available

  5. WANG C, Geng X, Abdelrahman S, Fu Y, et al
    A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.
    Blood. 2026;148:1816-1832.
    PubMed         Abstract available


    BMC Cancer

  6. VON KROGE S, Steinhaus NJ, Bokemeyer C, Tetzlaff F, et al
    Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study.
    BMC Cancer. 2026;26:1144.
    PubMed         Abstract available


    Br J Haematol

  7. TAO Y, Falade AS, Ogbue OD, Adeoye O, et al
    Autologous haematopoietic stem cell transplant consolidation and survival outcomes in primary central nervous system lymphoma: Evidence from the National Cancer Database.
    Br J Haematol. 2026 Sep 30. doi: 10.1111/bjh.70861.
    PubMed        

  8. CHOHAN KL, Feng L, Cochran H, Rosenberg M, et al
    Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2026 Sep 27. doi: 10.1111/bjh.70854.
    PubMed         Abstract available


    Cancer Lett

  9. YAO Y, Liu Y, Yan F, Li X, et al
    CD70-driven immunosuppression in mantle cell lymphoma identifies a vulnerability to CD70-Directed bispecific antibody modalities.
    Cancer Lett. 2026;661:218855.
    PubMed        


    Eur J Haematol

  10. THOMOPOULOS TP, Apostolopoulou C, Vryttia P, Bouchla A, et al
    Beyond Extranodal Site Count: Clinical and Anatomical Characterization of Primary Multifocal Extranodal Diffuse Large B-Cell Lymphoma.
    Eur J Haematol. 2026 Oct 1. doi: 10.1111/ejh.70335.
    PubMed         Abstract available


    Haematologica

  11. STUVER R, Drill E, Michaud L, Casulo C, et al
    Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma.
    Haematologica. 2026 Oct 1. doi: 10.3324/haematol.2026.301587.
    PubMed         Abstract available

  12. ARRIBAS AJ, Zadro A, Civanelli E, Sartori G, et al
    BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax.
    Haematologica. 2026 Oct 1. doi: 10.3324/haematol.2026.300780.
    PubMed         Abstract available

  13. HOOGSTRA DJ, Xavier AC, Harker-Murray P, Alexander S, et al
    Immune checkpoint therapy in pediatric and adolescent lymphomas.
    Haematologica. 2026;111:3220-3234.
    PubMed         Abstract available

  14. TZIONI MM, Watanabe N, Stelloo E, Chen Z, et al
    Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.
    Haematologica. 2026;111:3330-3345.
    PubMed         Abstract available


    Hum Pathol

  15. KIM H, Na S, Jeon YK, Lee JO, et al
    Nodal large B-cell lymphoma with intrasinusoidal growth: a clinicopathologic study of a distinctive pattern with diagnostic overlap with intravascular large B-cell lymphoma.
    Hum Pathol. 2026 Oct 1:106274. doi: 10.1016/j.humpath.2026.106274.
    PubMed         Abstract available


    J Natl Cancer Inst

  16. ROGERS JR, Ward ZJ, Feraco AM, Castellino SM, et al
    Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival.
    J Natl Cancer Inst. 2026 Oct 1:djag353. doi: 10.1093.
    PubMed         Abstract available


    Leukemia

  17. YAO Y, Yan F, Li X, Li Y, et al
    ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities.
    Leukemia. 2026 Oct 1. doi: 10.1038/s41375-026-03146.
    PubMed        


    Neurology

  18. MERSALI S, Chapelle R, Ribeiro M, Weiss N, et al
    Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy.
    Neurology. 2026;107:e218561.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum